,
“We are very pleased to be partnering with the stellar leadership of the
The finalists were selected from a pool of exceptional candidates across more than 20 countries and represent a diverse range of companies and research institutions developing innovative therapeutic solutions. Each finalist has demonstrated a commitment to advancing healthcare through creativity and groundbreaking research, with the ultimate goal of addressing unmet patient need for diseases of prevalence in the
- Algen Biotechnologies,
Chun-Hao Huang , PhD, Co-Founder & CEO - AnaCardio, Patrik Strömberg, PhD, CEO
- Chimera Therapeutics,
Matthew Lorence , PhD, Co-Founder & CEO - Harmonic Discovery,
Rayees Rahman , PhD, CEO - Lactocore,
Anton Malyshev , PhD, Founder & CEO - Medicovestor, Seah Lim, PhD, CEO
- Oncoheroes Biosciences,
Cesare Spadoni , PhD, Co-Founder & COO - Paradox Immunotherapeutics,
Natalie Galant , PhD, Co-Founder & CEO - SaudiVax,
Mazen Hassanain , PhD, CEO - Ypsilon Therapeutics,
Dongxing Zha , PhD, Founder & CEO - ZTI Biosciences,
Jaden Hyungseok Chang , PhD, CEO
The finalists will be judged by an esteemed panel, which includes:
-
Laurie Glimcher , MD, President and CEO atDana-Farber Cancer Institute -
Jorge Guzman , MD, CEO at Cleveland Clinic Abu Dhabi - Prof.
Shahrukh Khurshid Hashmi , Director of Research atDepartment of Health , Abu Dhabi -
David Hung , MD, Founder, President and CEO at Nuvation Bio -
Yasmine Hayek Kobeissi , PhD, CQF, BSc., Executive Director atBlue Horizon Advisors -
Anya Schiess , Managing Partner atJ.P. Morgan Life Sciences Private Capital
“We are grateful to these preeminent scientists and business leaders for coming to
In addition to the pitch competition, where winners will ultimately be awarded, the summit will feature keynote speeches and networking opportunities to provide attendees with investment opportunities and valuable insights into the future of life sciences innovation. Learn more about the finalists and summit here.
About
For more information:
.
About
About
BHLS is committed to enhancing health through research and development of innovative therapies and diagnostic tools to improve and prolong lives. BHLS is poised to execute its strategic vision through a multifaceted approach, encompassing strategic acquisitions, robust in-house development initiatives, dynamic joint ventures with global industry leaders / innovators to foster knowledge exchange, and pivotal collaborations with key stakeholders in our ecosystem, including esteemed hospitals, renowned universities, regulatory authorities as well as local and global investment houses.
View original content to download multimedia:https://www.prnewswire.com/news-releases/jp-morgan-life-sciences-private-capital-blue-horizon-advisors-and-united-alsaqer-group-announce-finalists-of-the-2024-life-sciences-innovation-summit-in-abu-dhabi-302108427.html
SOURCE